The Europe Insulin Syringes Market would witness market growth of 3.7% CAGR during the forecast period (2021-2027).
The World Health Organization (WHO) wants to encourage and promote the implementation of efficient diabetes monitoring, preventive, and control methods, especially in low- and middle countries. WHO accomplishes this by developing scientific regarding the prevention of major noncommunicable diseases, such as diabetes; developing norms and standards for diabetes care and diagnosis; raising awareness of the global diabetes epidemic by commemorating World Diabetes Day (November 14); and conducting diabetes and risk factor surveillance.
Due to the surge in diabetes cases, companies are launching insulin syringes on a massive scale. For example, Abbott and Novo Nordisk today announced a non-exclusive cooperation to incorporate insulin dosage data from Novo Nordisk pre-filled and durable linked pens straight into digital health solutions compatible with the FreeStyle Libre system on February 20, 2019. Both firms are committed to making diabetes care easier by linking important technologies like continuous glucose monitoring (CGM) and linked insulin pens.
Diabetes is becoming more common among people of all ages in Europe, owing to rising rates of overweight and obesity, poor food, and physical inactivity. Cardiovascular illness (mainly heart disease and stroke) kills 50 percent of diabetics, whereas kidney failure kills 10-20 percent of diabetics. In the European Region, around 60 million individuals have diabetes, accounting for 10.3 percent of men and 9.6 percent of women aged 25 and above.
The Germany market dominated the Europe Insulin Syringes Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $137.9 million by 2027. The UK market would showcase a CAGR of 2.9% during (2021 - 2027). Additionally, The France market is expected to witness a CAGR of 4.5% during (2021 - 2027).
Based on Disease, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Syringe Size, the market is segmented into 3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml) and Others. Based on End User, the market is segmented into Hospitals & Clinics, Homecare Settings, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Insulin Syringes Market Size will Hit $2.1 Billion by 2027, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hindustan Syringes & Medical Devices Ltd., Novo Nordisk A/S, Biocon Limited, Eli Lilly and Company, Abbott Laboratories, Becton, Dickinson and Company, Cardinal Health, Inc., Medline Industries, Inc., Terumo Corporation, and Nipro Corporation.
By Disease
By Syringe Size
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 